I'm not sure this is the best thread for this, but here it is...

I'm not sure this is the best thread for this, but here it is FWIW.

I believe shareholders need to ask themselves two questions:


1. In my carefully considered, non-emotional opinion, does the technology have the potential to earn money for shareholders by improving health outcomes for many health conditions, world wide?


2. In my carefully considered, non-emotional opinion, does the current management team have the capability and drive to earn money for shareholders using this technology.

From the presentation, my takeaway is that TK's answer to question 2 is in the negative, and his answer to question 1 is not a strong positive. YMMV.